(MENAFN- ProactiveInvestors)A fairly quiet day on the small cap front if not elsewhere but there were some notable announcements. Marketing analytics specialist Ebiquity (LON:EBQ) saw double-digit revenue and profit growth in the year to end April and has declared a maiden dividend. The group whose shares nudged higher on Tuesday after delivering forecast-beating numbers said it entered the new year with a pipeline of opportunities and is confident of growth. The firm enjoyed particularly strong growth in both the media value measurement (MVM) and marketing performance optimisation (MPO) divisions - which together account for 65% of the group (2014: 60%) - with combined like for like constant currency revenue growth rates of 14.7%. Elsewhere Mosman Oil and Gas (LON:MSMN) raised £400000 from a placing to move forward the acquisition of a producing asset along and arrange for it to be farmed-out. The shares were issued at 1.75p and the money raised today will pay a 10% non-refundable cash deposit. Last week the New Zealand-based group was granted preferred bidder status on the deal. Details released today indicated the project would cost £4.2 mln and contains onshore oil and gas producing fields and reserves and resources of approximately 8mln barrels. Toronto-listed junior Medgold (CVE:MED) said it was 'very pleased' with latest drill findings from the Lagares gold project in Portugal which showed further mineralisation at or near surface. Results of recent assays included 7.76m at 4.40 g/t gold in one hole and 10.53m at 3.07 g/t Au from 17.53m down-hole in another diamond drilled hole. Results have now been received for the first eight holes from this initial phase of drilling. Bergen Global has been issued with £280000 of Motive TV's (LON:MTV) shares after it exercised a conversion notice under a 2014 agreement with the firm it was reported today. Globo (LON:GBO) moved to calm any potential investor fears over Greece's financial situation amid its own share price fall. The organiser app specialist said it noted the "significant move in its share price since" July 22 but was "not aware of any material reason for the decline" and reiterated that that there was "no financial or operational impact expected as a result of this turmoil". "Since Greece has entered into an agreement with its lenders we see the Greek market returning to a degree of normality over the coming weeks and months" it said. Globo hails from Greece though in 2014 only 12% revenue was generated there with all of that income collected. In the current year growth elsewhere will reduce Greece's contribution to between 6-7% of the sales total. Finally life sciences group Optibiotix (LON:OPTI) has completed a clinical study for its cholesterol reducing capsules with no safety concerns arising. Human testing which began in January has been carried out over 12 weeks at the University of Reading on 50 people with high cholesterol. Samples from the volunteers will now be tested and analysed to determine the potential of the cholesterol lowering product. Stephen O'Hara chief executive said: 'The key point to get across is that the study was finished on time. We had no issues and no dropouts."
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.